Research programme: vitronectin receptor inhibitorsAlternative Names: Vitronectin receptor inhibitors - research programme - Wistar
Latest Information Update: 23 Apr 2002
At a glance
- Originator Nonindustrial source
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 17 Feb 2000 Preclinical development for Malignant melanoma in USA (Unknown route)
- 17 Feb 2000 New profile